Contribution of 18 Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma

Ferlay J , Soerjomataram I , Dikshit R , Eser S , Mathers C , Rebelo M , Parkin DM , Forman D , Bray F . Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136: E359-E386.

Siegel R , Naishadham D , Jemal A . CA Cancer J Clin. 2013 Jan; 63(1): 11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17

Yarden Y and Sliwkowski MX . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb; 2(2): 127-37.

Sordella R , Bell DW , Haber DA and Settleman J . Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20; 305(5687): 1163-7.

Takano T , Fukui T , Ohe Y , Tsuta K , Yamamoto S , Nokihara H , Yamamoto N , Sekine I , Kunitoh H , Furuta K , Tamura T . EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J. Clin. Oncol. 2008; 26: 5589-5595.

Lynch TJ , Bell DW , Sordella R , Gurubhagavatula S , Okimoto RA , Brannigan BW , Harris PL , Haserlat SM , Supko JG , Haluska FG , Louis DN , Christiani DC , Settleman J and Haber DA . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer gefitinib. N Engl J Med. 2004 May 20; 350: 2129-2139.

Paez JG , Jänne PA , Lee JC , Tracy S , Greulich H , Gabriel S , Herman P , Kaye FJ , Lindeman N , Boggon TJ , Naoki K , Sasaki H , Fujii Y , Eck MJ , Sellers WR , Johnson BE and Meyerson M . EGFR mutations in Lung Cancer: Correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4; 304(5676): 1497-1500.

Jorissen RN , Walker F , Pouliot N , Garrett TP , Ward CW and Burgess AW . Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003 Mar 10; 284(1): 31-53.

Marchetti A , Felicioni L and Buttitta F . Assessing EGFR mutations. N Engl J Med. 2006; 354: 526-8.

Vanuytsel LJ , Vansteenkiste JF , Stroobants SG , De Leyn PR , De Wever W , Verbeken EK , Gatti GG , Huyskens DP and Kutcher GJ . The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography(FDG-PET)lymph node staging on the radiation treatment volumes in patients with nonsmall cell lung cancer. Radiother Oncol. 2000 Jun; 55(3): 317-24.

Shiraishi K , Nomori H , Ohba Y , Kaji M , Mori T , Shibata H , Oya N and Sasaki J . Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvan treatment in nonsmall cell lung cancer: comporison with computed tomography. Ann Thorac Cardiovasc Surg. 2010 Dec; 16(6): 394-400.

Kurata T , Oguri T , Isobe T , Ishioka S and Yamakido M . Differential expression of facilitative glucose transporter(GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999 Nov; 90(11): 1238-1243.

Mamede M , Higashi T , Kitaichi M , Ishizu K , Ishimori T , Nakamoto Y , Yanagihara K , Li M , Tanaka F , Wada H , Manabe T and Saga T . (18F) FDG uptake and PCNA, Glut-1,and Hexokinase-II expressions in cancers and inflamatory lesions of the lung. Neoplasia. 2005 Apr; 7(4): 369-79.

Weihua Z , Tsan R , Huang WC , Wu Q , Chi CH , Fidler IJ and Hung MC . Survival of cancer cells in maintained by EGFR independent of it's kinase activity. Cancer Cell. May; 13(5): 385-393.

Shanzhi W , Yiping H , Ling H , Jianming Z and Qiang L . The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLos One. 2014 Apr 17; 9(4): e954794.

Sun PL , Seol H , Lee HJ , YooS B , Kim H , Xu X , Jheon S , Lee CT , Lee JS and Chung JH . High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012 Feb; 7(2): 323-30.

Nomura M , Shigematsu H , Li L , Suzuki M , Takahashi T , Estess P , Siegelman M , Feng Z , Kato H , Marchetti A , Shay JW , Spitz MR , Wistuba II , Minna JD and Gazdar . Polymorphisms, mutations and amplification of the EGFR gene in nonsmall lung Cancers. PloS Med. 2007 Apr; 4(4): e125.

Lortet Tieulent J , Soerjomataram I , Ferlay J , Rutherford M , Weiderpass E and Bray F . International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014 Apr; 84(1): 13-22.

Shepherd FA , Crowley J , Van Houtte P , Postmus PE , Carney D , Chansky K , Shaikh Z and Goldstraw P . The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small-cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007 Dec; 2(12): 1067-77.

Travis WD , Giroux DJ , Chansky K , Crowley J , Asamura H , Brambilla E , Jett J , Kennedy C , Rami-Porta R , Rusch VW and Goldstraw P . The IASLC Lung Cancer Staging Project: Proposals for the inclusion of Carcinoid tumours in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2008; 3(11): 1213-23.

Tan D , Li Q , Deeb G , Ramnath N , Slocum HK , Brooks J , Cheney R , Wiseman S , Anderson T , Loewen G . Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003 Jun; 34(6): 597-604.

D'Addario G , Rauch D , Stupp R , Pless M , Stahel R , Mach N , Jost L , Widmer L , Tapia C , Bihl M , Mayer M , Ribi K , Lerch S , Bubendorf L and Betticher DC . Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small - cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol. 2008 Apr; 19(4): 739-745.

Hinkova K , Babal P , Berzinec P , Majer I and Ilencikova D . Papid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis. Mol Diagn Ther. 2011 Feb 1; 15: 21-29.

Paez JG , Jänne PA , Lee JC , Tracy S , Greulich H , Gabriel S , Herman P , Kaye FJ , Lindeman N , Boggon TJ , Naoki K , Sasaki H , Fujii Y , Eck MJ , Sellers WR , Johnson BE and Meyerson M . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4; 304: 1497-500.

Lynch TJ , Bell DW , Sordella R , Gurubhagavatula S , Okimoto RA and Brannigan BW . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350(21): 2129-39.

Keedy VL , Temin S , Somerfield MR , Beasley MB , Johnson DH , McShane LM , Milton DT , Strawn JR , Wakelee HA and Giaccone G . American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011 May 20; 29(15): 2121-7.

Na II , Byun BH , Kim KM , Cheon GJ , Choe du H , Koh JS , Lee DY , Ryoo BY , Baek H , Lim SM , Yang SH , Kim CH and Lee JC . 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-instutation retrospectively analysis. Lung Cancer. 2010 Jan; 67(1): 76-80.

Mak RH , Digumarthy SR , Muzikansky A , Engelman JA , Shepard JA , Choi NC and Sequist LV . Role of 18F-Fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in nonsmall cell lung cancer. Oncologist. 2011; 16: 319-26.

Yoshino I , Ichinose Y , Nagashima A , Takeo S , Motohiro A , Yano T , Yokoyama H , Ueda H , Sugio K , Ishida T , Yasumoto K and Maehara Y . Kyushu Lung Cancer Surgery Cooperative Group. Clinical characterization of node-negative lung adenocarcinoma: results of a prospective investigation. J Thorac Oncol. 2006 Oct; 1: 825-31.

Vesselle H , Salskov A , Turcotte E , Wiens L , Schmidt R , Jordan CD , Valliéres E and Wood DE . Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology and Ki-67 proliferation index. J Thorac Oncol. 2008 Sep; 3(9): 971-8.

Huang CT , Yen RF , Cheng MF , Hsu YC , Wei PF and Tsai YJ . Correlation of F-18 fluodeoxyglucose-positron emission tomography maximal standardized uptake value EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010; 27: 9-15.

Ko KH , Hsu HH , Huang TW , Gao HW , Shen DHY , Chang WC , Hsu YC , Chang TH , Chu CM , Ho CL and Chang H . Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging. 2014; 41: 1889-1897.

Li M , Sun Y , Liu Y , Han A , Zhao S , Ma L , Zheng J and Yu J . Relationship between primary lesion FDG uptake and clinical stage at PET-CT for non-small cell lung cancer patients: An observation. Lung Cancer. 2010 Jun; 68(3): 394-7.

Lee EY , Khong PL , Lee VH , Qian W , Yu X , Wong MP . Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor. Clin Nucl Med. 2015 Mar: 40(3): e 190-5.

Gillies RJ , Robey I and Gatenby RA . Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008; 49(suppl): 24S-42S.

Plathow C and Weber WA . Tumor cell matabolism imaging. J Nucl Med. 2008 Jun; 49(suppl): 43S-63S.

Taylor MD , Smith PW , Brix WK , Wick MR , Theodosakis N , Swenson BR , Kozower BD , Lau CL and Jones DR . Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009 Jan; 137(1): 43-8.

Takahashi R , Hirata H , Tachibana I , Shimosegawa E , Inoue A and Nagatomo I . Early 18-FDG positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012 Jan 1; 18(1): 220-8.

Sunaga N , Oriuchi N , Kaira K , Yanagitani N , Tomizawa Y , Hisada T , Ishizuka T , Endo K and Mori M . Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008 Feb; 59(2): 203-10.

Yamaguchi T , Yanagisawa K , Sugiyama R , Hosono Y , Shimada Y , Arima C , Kato S , Tomida S , Suzuki M , Osada H and Takahashi T . NKX2-1/TITF1/TTF-1-Induced ROR 1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012 Mar 20; 21: 348-361.

Berghmans T , Paesmans M , Mascaux C , Martin B , Meert AP , Haller A , Lafitte JJ and Sculier JP . Thyroid transcription factor1-a new prognostic factor in lung cancer: A meta - analysis. Ann Oncol. 2006 Nov; 17: 1673-1676.

Pao W , Wang TY , Riely GJ , Miller VA , Pan Q , Ladanyi M , Zakowski MF , Heelan RT , Kris MG and Varmus HE . KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Plos Med. 2005 Jan; 2: e17.